In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 35099994.
- Also identified by DOI 10.7326/J21-0019.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Spyropoulos AC, Goldin M, Giannis D, et al. <b>Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial.</b> JAMA Intern Med. 2021;181:1612-20. 34617959.
Medical subject headings
- COVID-19
- Venous Thromboembolism